We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Supports Amarin’s Vascepa for Cardiovascular Events
Advisory Committee Supports Amarin’s Vascepa for Cardiovascular Events
An FDA advisory committee voted unanimously on Thursday to recommend approval of Amarin Pharmaceuticals’ Vascepa (icosapent ethyl) to reduce the risk of cardiovascular events in adults.